Centogene Valuation Multiples

Discover Centogene's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Ludwig Enterprises, Lifeline Biotechnologies, GenIP, 2cureX and more.

Centogene Overview

About Centogene

Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.


Founded

2018

HQ

Germany

Employees

493

Financials (FY)

Revenue: $56M
EBITDA: ($22M)

EV

$76M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Centogene Financials

Centogene reported last fiscal year revenue of $56M and negative EBITDA of ($22M).

In the same fiscal year, Centogene generated $20M in gross profit, ($22M) in EBITDA losses, and had net loss of ($41M).


Centogene P&L

In the most recent fiscal year, Centogene reported revenue of $56M and EBITDA of ($22M).

Centogene is unprofitable as of last fiscal year, with gross margin of 36%, EBITDA margin of (40%), and net margin of (73%).

See analyst estimates for Centogene
Last FY2023202620272028
Revenue$56M$56M
Gross Profit$20M$20M
Gross Margin36%36%
EBITDA($22M)($22M)
EBITDA Margin(40%)(40%)
EBIT Margin(74%)(74%)
Net Profit($41M)($41M)
Net Margin(73%)(73%)
Net Debt$55M-

Financial data powered by Morningstar, Inc.

Centogene Stock Performance

Centogene has current market cap of $3M, and enterprise value of $76M.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$76M$3M-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Centogene Valuation Multiples

Centogene trades at 1.4x EV/Revenue multiple, and (3.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Centogene

Centogene Financial Valuation Multiples

As of July 17, 2026, Centogene has market cap of $3M and EV of $76M.

Centogene has a P/E ratio of (0.1x).

Last FY2023202620272028
EV/Revenue1.4x1.4x
EV/EBITDA(3.4x)(3.4x)
EV/EBIT(1.8x)(1.8x)
EV/Gross Profit3.8x3.8x
P/E(0.1x)(0.1x)
EV/FCF(1.9x)(1.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Centogene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Centogene Margins & Growth Rates

In the most recent fiscal year, Centogene reported gross margin of 36%, EBITDA margin of (40%), and net margin of (73%).

See estimated margins and future growth rates for Centogene

Centogene Margins

Last FY202720282029
Gross Margin36%
EBITDA Margin(40%)
EBIT Margin(74%)
Net Margin(73%)
FCF Margin(70%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Centogene Operational KPIs

Centogene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Centogene
Last FY2023202620272028
Revenue per Employee$0.1M-
Opex per Employee$0.1M-
S&M Expenses to Revenue26%26%
G&A Expenses to Revenue60%60%
R&D Expenses to Revenue25%25%
Opex to Revenue110%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Centogene Competitors

Centogene competitors include Ludwig Enterprises, Lifeline Biotechnologies, GenIP, 2cureX, Integragen, Fluicell, Epigenomics, Diagonal Bio, AcouSort and NRGene.

Most Centogene public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ludwig Enterprises--(4.4x)-
Lifeline Biotechnologies----
GenIP1.7x-(0.8x)-
2cureX--(9.0x)-
Integragen0.0x-(1.5x)-
Fluicell4.4x-(3.3x)-
Epigenomics492.1x-(37.6x)-
Diagonal Bio----

This data is available for Pro users. Sign up to see all Centogene competitors and their valuation data.

Start Free Trial

Centogene VC Funding History

Before going public, Centogene raised $29M in total equity funding, across 1 round.


Centogene Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jun-17Series ADPE Deutsche Private Equity; Careventures; CIC Capital; TVM Capital Life Science$29M-Centogene is a biotechnology company focused on rare diseases, developing a global proprietary platform based on real-world data with billions of data points. For the year ended December 31, 2017, Centogene generated total revenue of €31.7 million. This figure aligns closely with the timing of the mid-2017 funding round. Subsequent financials show growth: €40.5 million revenue in 2018, €42.2 million in 2021, €47.5 million in 2022 (12% YoY growth), and €48.5 million in 2023 (2% YoY growth). The company operates Diagnostics (€33.7 million in 2023) and Pharma (€14.8 million in 2023) segments, with adjusted EBITDA of €11.1 million in 2023.

Acquisitions by Centogene

Centogene has acquired 1 company to date.

Last acquisition by Centogene was on July 7th 2026. Centogene acquired Pearl Medical Analysis Laboratory for $10M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Centogene

Pearl Medical Analysis Laboratory
Description
Pearl Medical Analysis Laboratory is a diagnostics facility that runs genetic and reproductive testing from its location in Abu Dhabi.
HQ CountryUnited Arab Emirates
HQ City
Abu Dhabi
Deal Date7 Jul 2026
Valuation$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Centogene acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Centogene

When was Centogene founded?Centogene was founded in 2018.
Where is Centogene headquartered?Centogene is headquartered in Germany.
How many employees does Centogene have?As of today, Centogene has over 493 employees.
Is Centogene publicly listed?Yes, Centogene is a public company listed on OTCM.
What is the stock symbol of Centogene?Centogene trades under CNTGF ticker.
When did Centogene go public?Centogene went public in 2019.
Who are competitors of Centogene?Centogene main competitors include Ludwig Enterprises, Lifeline Biotechnologies, GenIP, 2cureX, Integragen, Fluicell, Epigenomics, Diagonal Bio, AcouSort, NRGene.
What is the current market cap of Centogene?Centogene's current market cap is $3M.
What is the current revenue of Centogene?Centogene's last fiscal year revenue is $56M.
What is the current EV/Revenue multiple of Centogene?Current revenue multiple of Centogene is 1.4x.
Is Centogene profitable?No, Centogene is not profitable.
How many companies Centogene has acquired to date?As of July 2026, Centogene has acquired 1 company.
What was the largest acquisition by Centogene?$10M acquisition of Pearl Medical Analysis Laboratory on 7th July 2026 was the largest M&A Centogene has done to date.
What companies Centogene acquired?Centogene acquired Pearl Medical Analysis Laboratory.
In how many companies Centogene has invested to date?Centogene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Centogene

Lists including Centogene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial